Phase 2 Serous Ovarian Cancer Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 2
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center20 enrolled8 locationsNCT06394804
Recruiting
Phase 2
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Cervical CancerSolid TumorHigh Grade Serous Ovarian Cancer+2 more
University of Oklahoma55 enrolled4 locationsNCT05512208
Recruiting
Phase 2
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Ovarian CancerSerous Ovarian Cancer
Sarah K. Lynam MD31 enrolled1 locationNCT05113368
Withdrawn
Phase 2
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
High Grade Serous Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group40 enrolled8 locationsACTRN12619000583145
Recruiting
Phase 2
Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer
Platinum Sensitive Serous Ovarian Cancer
Astra Zeneca250 enrolled9 locationsACTRN12609000159257